Fredun Pharmaceuticals Ltd. (FREDUN) Share Price Rises 16.24% Today

Fredun Pharmaceuticals Ltd. Share Price rose 16.24% today, reaching Rs 1,290 with a market cap of Rs 1,740.47 crore.

Fredun Pharmaceuticals Ltd. Share Price experienced a significant rise today, closing at Rs 1,290, marking a 16.24% increase from its previous close of Rs 1,109.75. This notable price movement places the company's market capitalisation at Rs 1,740.47 crore, categorising it within the Small Cap segment. The substantial gain in Fredun Pharmaceuticals Ltd. However, the data does not indicate a specific catalyst driving this price rise.

The stock opened at Rs 1,120.9 and fluctuated between a high of Rs 1,331.7 and a low of Rs 1,084 during the trading session. With a total volume of 172,034 shares traded on the BSE, the turnover reached Rs 22.19 crore. This level of activity highlights the market's interest in Fredun Pharmaceuticals Ltd. today.

Fredun Pharmaceuticals Ltd. (FREDUN) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,290
Previous Close	Rs 1,109.75
Today's Change	+Rs 180.25 (+16.24%)
Day Open	Rs 1,120.9
Day High	Rs 1,331.7
Day Low	Rs 1,084
Current Volume (BSE)	1,72,034
BSE Traded Volume	1,72,034
Combined NSE + BSE Volume	1,72,034
Turnover	Rs 22.19 crore
Market Capitalisation	Rs 1,740.47 crore
Market Cap Category	Small Cap

Fredun Pharmaceuticals Ltd. (FREDUN) traded at Rs 1,290. versus the previous close of Rs 1,109.75, a rise of 16.24%. The stock opened at Rs 1,120.9, reached Rs 1,331.7, touched Rs 1,084. Reported volume was 1,72,034.

Fredun Pharmaceuticals Ltd. (FREDUN) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 1,740.47 crore
P/E Ratio	56.26x
P/B Ratio	6.55x
ROE	11.42%
ROCE	13.15%
EPS	Rs 19.72
Dividend Yield	0.02%

Fredun Pharmaceuticals Ltd. was valued at a P/E ratio of 56.26x, a P/B ratio of 6.55x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 11.42% and ROCE of 13.15%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 19.72, dividend yield of 0.02%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Fredun Pharmaceuticals Ltd. has a market capitalisation of Rs 1,740.47 crore, positioning it within the Small Cap category. The company's Price-to-Earnings (P/E) ratio is 56.26, which is higher than the industry median of 25.82 but below the average of 80.86. This suggests that while the stock is relatively expensive compared to its peers, it is not excessively overvalued within the industry context.

The Price-to-Book (P/B) ratio is 6.55, significantly above the industry median of 1.85, indicating a high valuation relative to its book value. The Return on Equity (ROE) is 11.42%, slightly above the industry median of 10.59%, reflecting efficient use of shareholder equity. The Return on Capital Employed (ROCE) is 13.15%, aligning closely with the industry median of 12.98%.

Fredun Pharmaceuticals Ltd.'s Earnings Per Share (EPS) stands at Rs 19.72, and the dividend yield is a modest 0.02%. These figures provide insight into the company's profitability and shareholder returns. The fundamental analysis highlights the need for investors to consider both valuation and financial performance when assessing the stock's potential.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	56.26x
Benchmark Median P/E	25.82x
Benchmark Average P/E	80.86x
Benchmark P/E Range	3.39x to 3,385.56x
Company P/B Ratio	6.55x
Benchmark Median P/B	1.85x
Company ROE	11.42%
Benchmark Median ROE	10.59%
Company ROCE	13.15%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 1,740.47 crore
Benchmark Median Market Cap	Rs 146.67 crore

Fredun Pharmaceuticals Ltd. (FREDUN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 56.26x, which is above the benchmark median of 25.82x, a difference of +117.89%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Fredun Pharmaceuticals Ltd. (FREDUN) has a ROE of 11.42%, which is above the benchmark median of 10.59%, a difference of +7.84%. Fredun Pharmaceuticals Ltd. (FREDUN) has a ROCE of 13.15%, which is above the benchmark median of 12.98%, a difference of +1.31%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Fredun Pharmaceuticals Ltd. operates within the Healthcare sector, specifically in the Pharmaceuticals & Drugs industry. The industry comprises 137 companies, with Fredun Pharmaceuticals Ltd.'s P/E ratio of 56.26 positioned above the industry median of 25.82. This suggests a higher valuation compared to many peers, though it remains below the industry average of 80.86.

The company's P/B ratio of 6.55 is significantly higher than the industry median of 1.85, indicating a premium valuation. In terms of profitability, Fredun Pharmaceuticals Ltd.'s ROE of 11.42% is above the industry median of 10.59%, while its ROCE of 13.15% is slightly above the median of 12.98%.

The market capitalisation of Fredun Pharmaceuticals Ltd. at Rs 1,740.47 crore is above the industry median of Rs 146.67 crore, reflecting its relative size within the sector. The company's performance within the sector highlights its competitive positioning and valuation dynamics.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,945.17	30.21	0.44	-2.89	-0.26
Hikal Ltd.	HIKAL	2,835.92	0	2.35	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,652.68	39.86	8.11	28.21	26.35
Beta Drugs Ltd.	BETA	2,608.51	63.2	10	18.65	22.17
Panacea Biotec Ltd.	PANACEABIO	2,589.99	0	3.07	0	5.36

Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 56.26x compared with the displayed peer median of 30.21x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.42% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 13.15% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Fredun Pharmaceuticals Ltd. (FREDUN) has a market capitalisation of Rs 1,740.47 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

In comparison to its peers, Fredun Pharmaceuticals Ltd. exhibits a higher P/E ratio of 56.26, compared to Dishman Carbogen Amcis Ltd. at 30.21 and Kwality Pharmaceuticals Ltd. at 39.86. Its P/B ratio of 6.55 is also higher than many peers, such as Hikal Ltd. at 2.35 and Solara Active Pharma Sciences Ltd. at 1.97.

Fredun Pharmaceuticals Ltd.'s ROE of 11.42% is lower than Kwality Pharmaceuticals Ltd.'s 28.21% but higher than Dishman Carbogen Amcis Ltd.'s -2.89%. The company's ROCE of 13.15% is below Beta Drugs Ltd.'s 22.17% but above Panacea Biotec Ltd.'s 5.36%.

This peer comparison underscores Fredun Pharmaceuticals Ltd.'s valuation and profitability relative to its industry counterparts, providing a comprehensive view of its market position.

Why Investors Are Watching Fredun Pharmaceuticals Ltd.

Fredun Pharmaceuticals Ltd. has captured investor attention due to its significant price rise today. The stock's performance, coupled with its valuation and sector positioning, makes it a focal point for market participants.

• Price Action: A 16.24% increase in share price today.
• Technical Position: Neutral RSI at 54.01, indicating balanced momentum.
• Fundamental Context: High P/E and P/B ratios, with moderate ROE and ROCE.
• Sector Positioning: Operates in the Healthcare sector with a premium valuation.

Investors should monitor Fredun Pharmaceuticals Ltd.'s future performance, considering both market trends and company-specific developments.

About Fredun Pharmaceuticals Ltd.

Fredun Pharmaceuticals Ltd. is a prominent player in the Healthcare sector, specifically within the Pharmaceuticals & Drugs industry. The company focuses on the development, manufacturing, and marketing of pharmaceutical products. It operates across various segments, catering to diverse healthcare needs.

The company's product portfolio includes a wide range of pharmaceutical formulations, catering to both domestic and international markets. Fredun Pharmaceuticals Ltd. is committed to quality and innovation, striving to meet the evolving demands of the healthcare industry. Its strategic positioning within the sector underscores its potential for growth and market expansion.

Track Fredun Pharmaceuticals Ltd. Share Price on Univest

Use Fredun Pharmaceuticals Ltd. (FREDUN) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors can track Fredun Pharmaceuticals Ltd. Share Price on Univest, where they can access live share price updates, technical indicators, fundamental ratios, and shareholding patterns. Univest provides comprehensive market insights, including 52-week levels and sector performance, enabling investors to make informed decisions.

Frequently Asked Questions

What was Fredun Pharmaceuticals Ltd.'s share price increase today?

Ans. Fredun Pharmaceuticals Ltd.'s share price increased by 16.24% today, closing at Rs 1,290, up from the previous close of Rs 1,109.75. The stock moved 16.24% during the session. The intraday range extended from Rs 1,084 to Rs 1,331.7.

What is Fredun Pharmaceuticals Ltd.'s market capitalisation?

Ans. Fredun Pharmaceuticals Ltd.'s market capitalisation is Rs 1,740.47 crore, categorising it within the Small Cap segment. The company operates in the Healthcare sector. Its P/E ratio is 56.26x. ROE is 11.42% and ROCE is 13.15%.

What is Fredun Pharmaceuticals Ltd.'s P/E ratio?

Ans. Fredun Pharmaceuticals Ltd.'s P/E ratio is 56.26, higher than the industry median of 25.82 but below the average of 80.86. The company trades at a P/E ratio of 56.26x. Its P/B ratio is 6.55x.

How does Fredun Pharmaceuticals Ltd.'s ROE compare to the industry?

Ans. Fredun Pharmaceuticals Ltd.'s ROE is 11.42%, slightly above the industry median of 10.59%, indicating efficient use of shareholder equity. ROE stands at 11.42%. ROCE stands at 13.15%. The relevant peer median ROE is 10.59%.

How does Fredun Pharmaceuticals Ltd.'s P/B ratio compare to its peers?

Ans. Fredun Pharmaceuticals Ltd.'s P/B ratio of 6.55 is significantly higher than the industry median of 1.85, indicating a premium valuation. The company trades at a P/E ratio of 56.26x. Its P/B ratio is 6.55x.

How does Fredun Pharmaceuticals Ltd.'s market cap compare within its industry?

Ans. Fredun Pharmaceuticals Ltd.'s market cap of Rs 1,740.47 crore is above the industry median of Rs 146.67 crore, reflecting its relative size. The company operates in the Healthcare sector. Its P/E ratio is 56.26x.

What is Fredun Pharmaceuticals Ltd.'s ROCE?

Ans. Fredun Pharmaceuticals Ltd.'s ROCE is 13.15%, aligning closely with the industry median of 12.98%, indicating efficient capital use. ROE stands at 11.42%. ROCE stands at 13.15%. The relevant peer median ROE is 10.59%.